MASLD and MASH: Early Identification to Decrease Associated Complications-MASLD and MASHMASLD and MASH_ Early Identification to Decrease Associated Complications

MASLD and MASHMASLD and MASH_ Early Identification to Decrease Associated Complications

Video Transcription

Video Summary

Dr. Cecilia Lo Wang and Dr. Thomas Jensen from the University of Colorado School of Medicine provide a comprehensive overview of Metabolic Dysfunction Associated Steatotic Liver Disease (MASL-D), formerly NAFLD. MASL-D involves excess liver fat linked to cardiometabolic risk factors without other liver disease causes. Screening focuses on high-risk groups—those with obesity, diabetes, metabolic syndrome, or incidental steatosis—using FIB4 scores and imaging like ultrasound or FibroScan. Diagnosis of advanced disease, including MASH (Metabolic Dysfunction Associated Steatohepatitis) and fibrosis, may require biopsy, though non-invasive tests and imaging are increasingly used. Management centers on lifestyle modifications such as weight loss, healthy diet, exercise, and alcohol reduction, alongside pharmacological treatments like GLP-1 agonists, pioglitazone, vitamin E, and recently FDA-approved rosmetarone for MASH with fibrosis. Bariatric surgery is considered for eligible patients. Monitoring disease progression involves periodic non-invasive testing. Specialist referral is advised for advanced fibrosis or cirrhosis, emphasizing a multidisciplinary approach to manage comorbidities and improve outcomes.

Keywords

Metabolic Dysfunction Associated Steatotic Liver Disease

MASL-D

NAFLD

MASH

liver fibrosis

lifestyle modification